ArticleCancer2015

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.

Jorge E Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.